Recursion Pharmaceuticals benefits from Trump-era tariffs, reiterated Buy rating from Needham.
1 report, 1 independent
Updated Aug 24
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Recursion Pharmaceuticals benefits from Trump-era tariffs, reiterated Buy rating from Needham.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
Recursion (United States)
company in Salt Lake City, United States
Related events
- The new event concerns the impact of Trump-era tariffs and onshoring trends on Viatris.
- Trump's tariff plan caused markets to tank, impacting Donnelley Financial Solutions.
- The Institute for Supply Management noted on August 8, 2025, that tariffs from the Trump administration were causing market volatility and hurting industry and consumers.
- Elastic benefits from the trend of onshoring and tariffs associated with the Trump administration.
- Trump's tariff plan caused markets to tank, affecting company Flo.
Coverage
Newest first; wire copies grouped- Insider MonkeyNeedham Maintains Buy Rating on Recursion (RXRX) Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 10 Best Penny Stocks to Buy for the Next 5 Years. On August 5, Needham reiterated its Buy